Evotaz (Atazanavir Sulfate; Cobicistat) Tablet shortage
Possibly permanent — Bristol Myers Squibb, the only company we could find listing atazanavir sulfate; cobicistat tablets, has told the FDA it is discontinuing its product as of Oct 5, 2026. The FDA lists this under “To be discontinued”. We could not confirm another company listing the same medicine in the FDA NDC Directory, so talk with your prescriber about a long-term plan before your supply runs out.
Bristol Myers Squibb is stopping Evotaz (atazanavir/cobicistat) tablets, and this change is expected to be permanent. No other maker of this medicine has been found, so it may not be available from any source after the discontinuation takes effect.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Evotaz still in shortage? — status as of Oct 5, 2026
Still listed as “To be discontinued” as of Oct 5, 2026. We could not find another company that sells atazanavir sulfate; cobicistat tablets, so this may become permanent. Talk with your prescriber about a long-term plan before your supply runs out.
The charts count only the companies that reported this shortage to the FDA; we could not confirm another company listing it (see below).
Shortage timeline
-
Nov 3, 2025Currently in shortage1 of 1 product affected.
-
Nov 3, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Evotaz products are affected — by company
Company: Bristol Myers Squibb Co. 📞 800-332-2056 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Evotaz Tablet, 300 mg; 150 mg | 300 mg; 150 mg | — | The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026. | — |
These rows are company reports to the FDA for Atazanavir Sulfate; Cobicistat Tablet — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock.
Why is Bristol Myers Squibb discontinuing Evotaz?
Bristol-Myers Squibb has reported to the FDA that they plan to permanently stop making EVOTAZ® (atazanavir sulfate/cobicistat) tablets globally. According to their filing, manufacturing is currently estimated to cease starting in April 2026. The specific product affected is the 300 mg/150 mg tablet (the standard combination tablet).
No specific reason was shared publicly by the manufacturer for why they are stopping production — they simply did not provide one in this FDA report. What we do know is that this is a planned, permanent discontinuation of this product, not a temporary shortage or supply hiccup.
Based on the company-reported reason(s) and notes on file with the FDA for Atazanavir Sulfate; Cobicistat Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Evotaz?
Atazanavir sulfate with cobicistat — the combination tablet sold as Evotaz — is currently on the FDA shortage list, and the status reported is "to be discontinued."
Both strengths of this product are affected. The single combined tablet, which contains 300 mg of atazanavir and 150 mg of cobicistat, has no available source reported right now. There are no other strengths listed as still in supply.
The manufacturer on this record, Bristol Myers Squibb, reports a global cease-manufacture date for Evotaz estimated to begin April 2026. Because this is a planned discontinuation rather than a temporary delay, this supply issue may be permanent. That makes a conversation with your prescriber the right and important next step, so you have a plan well before supply runs low.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — your HIV medicines need to stay consistent.
- Ask your pharmacy to check wholesalers and any remaining stock, since supplies can still be on shelves.
- Talk with your prescriber or pharmacist soon about a clinician-chosen alternative, since this product is being discontinued.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Evotaz 300 mg/1; 150 mg | E.R. | 30 tablets | $52.048 | — | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Evotaz — that fall in the same broad treatment class (antivirals, hiv-specific, protease inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other antiviral shortages
Evotaz shortage FAQs
Is Evotaz still in shortage?
Which strengths of Evotaz are affected?
Which Evotaz products are affected?
When will Evotaz be available again?
Is the brand or the generic affected?
What should I do if I take Evotaz?
Still have a question about the Evotaz shortage?
Ask a pharmacist about this shortage →View Atazanavir Sulfate; Cobicistat Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.